Seamus Mulligan has served as a director of Emergent BioSolutions since 2019. Between 2014 and 2018, Mr. Mulligan served as chairman and chief executive officer of Adapt Pharma Ltd., a specialty pharmaceutical company, which was acquired in October 2018 by Emergent BioSolutions. Mr. Mulligan is also a member of the Jazz Pharmaceuticals plc. board of directors, having been appointed in January 2012 and served as their chief business officer, International Business Development from January 2012 until February 2013. Mr. Mulligan was a founder and principal investor of Azur Pharma and served as Azur Pharma’s chairman and chief executive officer and a member of its board of directors from 2005 until January 2012. From 2006 to April 2017, Mr. Mulligan was executive chairman of Circ Pharma Limited and its subsidiaries, a pharmaceutical development-stage group. From 1984 until 2004, he held various positions with Elan Corporation, plc, a pharmaceutical company, most recently as executive vice president, Business and Corporate Development, and prior to that position, held the roles of president of Elan Pharmaceutical Technologies, the drug delivery division of Elan Corporation, plc, executive vice president, Pharmaceutical Operations, vice president, U.S. Operations and vice president, Product Development. He served as a member of the board of directors of the U.S. National Pharmaceutical Council until 2004. Mr. Mulligan holds a Bachelor of Science in Pharmacy and a Master of Science from Trinity College, Dublin, Ireland.